Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 50 for:    CoreValve

Medtronic CoreValve Evolut R U.S. Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02207569
Recruitment Status : Active, not recruiting
First Posted : August 4, 2014
Results First Posted : December 12, 2017
Last Update Posted : May 1, 2019
Sponsor:
Information provided by (Responsible Party):
Medtronic Cardiovascular

Brief Summary:
The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.

Condition or disease Intervention/treatment Phase
Aortic Stenosis Device: CoreValve Evolut R TAVR system Not Applicable

Detailed Description:

This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving a minimum of 150 implanted subjects with no more than 250 implanted subjects at up to 25 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.

The enrollment phase of the study is estimated to take approximately 6-9 months. As each implanted subject is to be followed up to 5 years, the estimated study duration is approximately 66-69 months, excluding the time required for preparing the final report.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 241 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Medtronic CoreValve Evolut R United States IDE Clinical Study
Study Start Date : August 2014
Actual Primary Completion Date : August 2015
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CoreValve Evolut R TAVR system

The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:

  1. Evolut R Transcatheter Aortic Valve (TAV)
  2. EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
  3. EnVeo R Loading System (LS)
Device: CoreValve Evolut R TAVR system



Primary Outcome Measures :
  1. All-cause Mortality at 30 Days by Percent [ Time Frame: Assessed at 30 days post-implantation ]
    Percentage of patients that died by any cause at 30 days

  2. Percentage of Patients With Disabling Stroke at 30 Days [ Time Frame: Assessed at 30 days post-implantation ]

    Stroke Diagnostic Criteria:

    >

    Acute episode of focal or global neurological deficit with at least 2 of the following:

    • change in level of consciousness >
    • hemiplegia, hemiparesis
    • numbness or sensory loss affecting 1 side >
    • dysphasia or aphasia
    • hemianopia
    • amaurosis fugax >
    • other neurological signs or symptoms consistent with stroke

      2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist

      3.) Confirmation of the diagnosis by at least 1 of the following:

    • Neurological specialist >
    • Neuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death

    Defined by VARC II:

    > An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline


  3. Percent Device Success Rate Between 24 and 7 Day [ Time Frame: Assessed at 24 hours to seven days post implantation ]

    Percentage of patients with Device Success defined as:

    • Absence of procedural mortality, AND
    • Correct positioning of a single Evolut R valve into the proper anatomical location, AND
    • Absence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND
    • Absence of moderate or severe prosthetic valve regurgitation

  4. Percentage of Patients With Less Than Moderate Prosthetic Regurgitation at Early Post Procedure Echocardiogram (24 Hours to 7 Days) [ Time Frame: Assessed at 24 hours to 7 days post implantation ]
    Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.


Secondary Outcome Measures :
  1. Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR) [ Time Frame: Assessed at 30 days post-implantation ]
    Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.

  2. Coronary Artery Obstruction Requiring Intervention. [ Time Frame: Assessed at 30 days post-implantation ]
    Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.

  3. Percent VARC II Combined Safety Endpoint at 30 Days [ Time Frame: Assessed at 30 days post-implantation ]

    VARC II composite safety endpoint rate includes percent freedom from the following components:

    • All-cause mortality
    • All stroke (disabling and non-disabling)
    • Life-threatening bleeding
    • Acute kidney injury: stage 2 or 3 (including renal replacement therapy).
    • Coronary artery obstruction requiring intervention.
    • Major vascular complication.
    • Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)

  4. Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy). [ Time Frame: Assessed at 30 days post-implantation ]

    Stage 2

    1. Increase in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR

      >

    2. Urine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >

    1) Increase in serum creatinine to ≥300% (>3 x increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR

    • Urine output <0.3 ml/kg/h for ≥24 h OR

      >

    • Anuria for ≥12 h

  5. Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate [ Time Frame: Assessed at 30 days post-implantation ]
    1. Fatal bleeding (BARC type 5) OR

      >

    2. Bleeding in a critical organs, such as intracranial, intraspinal,

      > intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR

      >

    3. Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR

      >

    4. Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* > (BARC type 3b)

  6. Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days [ Time Frame: Assessed at 30 days ]
    Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure

  7. Percent Resheath and Recapture Success Rate [ Time Frame: Assessed intra-procedurally ]
    Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.

  8. Hemodynamic Performance -Mean Gradient [ Time Frame: Assessed at baseline, 30 days, 6 months, and 1 year ]
    Mean gradient by Doppler echocardiography.

  9. Major Vascular Complication [ Time Frame: Assessed at 30 days post-implantation ]
    1. Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR

      >

    2. Access-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR

      >

    3. Distal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR

      >

    4. The use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR

      >

    5. Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR

      >

    6. Surgery for access site nerve injury OR

      >

    7. Permanent access related nerve injury

  10. Hemodynamic Performance - Aortic Valve Area [ Time Frame: Assessed at baseline, 30 days, 6 months, and 1 year ]
    Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2

  11. Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe [ Time Frame: Assessed at 30 days, 6 months, and 1 year ]
    Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria - Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.

Subjects with low-flow/low gradient severe aortic stenosis can be included, provided low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient of >40 mmHg or a maximal aortic valve velocity of >4.0 m/sec, AND aortic valve area of <1.0cm2 (or aortic valve area index of <0.6 cm2/m2).

  • STS score of ≥ 8 OR documented heart team agreement of ≥ high risk for AVR due to frailty or co-morbidities.
  • Symptoms of aortic stenosis, AND NYHA Functional Class II or greater
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria

  • Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. subject is indicated for mechanical prosthetic valve).
  • A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin or heparin (HIT/HITTS) and bivalirudin, ticlopidine and clopidogrel, Nitinol (titanium or nickel), contrast media
  • Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.
  • Untreated clinically significant coronary artery disease requiring revascularization.
  • Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
  • End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min.
  • Ongoing sepsis, including active endocarditis.
  • Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to the study procedure.
  • Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
  • Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
  • Gastrointestinal (GI) bleeding that would preclude anticoagulation.
  • Subject refuses a blood transfusion.
  • Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
  • Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.
  • Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-ups exams.
  • Currently participating in an investigational drug or another device study (excluding registries).
  • Evidence of an acute myocardial infarction ≤ 30 days before the study procedure.
  • Need for emergency surgery for any reason.
  • Liver failure (Child-Pugh class C).
  • Subject is pregnant or breast feeding.

Anatomical exclusion criteria:

  • Pre-existing prosthetic heart valve in any position.
  • Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).
  • Severe mitral regurgitation.
  • Severe tricuspid regurgitation.
  • Moderate or severe mitral stenosis.
  • Hypertrophic obstructive cardiomyopathy.
  • Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus, or vegetation.
  • Congenital bicuspid or unicuspid valve verified by echocardiography.

For transfemoral or transaxillary (subclavian) acess:

- Access vessel diameter <5.0mm or <6.0mm for patent LIMA


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02207569


  Show 23 Study Locations
Sponsors and Collaborators
Medtronic Cardiovascular
Investigators
Layout table for investigator information
Principal Investigator: Jeffrey J Popma, MD Beth Israel Deaconess Medical Center
Principal Investigator: Mathew R Williams, MD New York Langone Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medtronic Cardiovascular
ClinicalTrials.gov Identifier: NCT02207569     History of Changes
Other Study ID Numbers: 10126779DOC
First Posted: August 4, 2014    Key Record Dates
Results First Posted: December 12, 2017
Last Update Posted: May 1, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction